Renin Co-Crystallization to Speed Cardiovascular Drug Discovery
News Aug 17, 2005
Renin inhibitors are currently under development for the treatment of hypertension, chronic renal disease and congestive heart failure.
A protease produced in the kidneys, renin cleaves angiotensinogen which is ultimately converted to angiotensin II, bringing about sodium retention and an increase in blood pressure.
Inhibiting renin in hypertensive individuals may provide benefits over current therapies to reduce blood pressure, decrease salt retention and may protect organs sensitive to hypertension such as the kidney, heart and brain.
ActiveSight's "ready-to-go" Portfolio Protein crystals are designed to allow pharmaceutical and biotech companies to take advantage of protein structure based drug design in their drug development programs, even if they do not have internal structural biology capabilities.
ActiveSight have said that clients can submit their lead compounds to it where they are co-crystallized with the Portfolio Protein of interest and the structure of the complex is solved, providing important, rapid lead development data to the client.
ActiveSight is employing crystallographic-grade recombinant human renin supplied by Proteos, Inc.
Global Experts Meeting on Frontiers in Biosimilars and Biologics Congress
Oct 24 - Oct 26, 2019